HC Wainwright & Co. Maintains Buy on OKYO Pharma, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on OKYO Pharma (NASDAQ:OKYO) and increased the price target from $6 to $7.
March 22, 2024 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OKYO Pharma's Buy rating was maintained by HC Wainwright & Co., with the price target raised from $6 to $7.
The maintenance of a Buy rating combined with an increased price target typically signals a positive outlook on the stock from the analyst, suggesting an expectation of upward price movement in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100